 Galera Therapeutics, Inc. GRTX, a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Linda B. West to its board of directors. Additionally, as part of a planned transition, Jason Fuller, Ph.D., will not stand for re-election at Galeras annual meeting. Linda is a proven and highly regarded business leader with extensive experience in transforming business operations, as well as spearheading governance, compliance and regulatory activities, said Mel Sorensen, M.D., President and CEO of Galera. 